Xiamen Kingdomway Group Co. (002626.SZ) Latest Company News

Oct 26, 2026, 09:57 UTC
Kingdomway disclosed first-three-quarter 2026 revenue of 2.636 billion yuan, up 1.22% year over year, and attributable net profit of 254 million yuan, down 29.67%.
Source:
- finance.sina.cn
Oct 26, 2026, 09:57 UTC
Kingdomway disclosed third-quarter 2026 revenue of 863 million yuan, down 1.46% year over year, and attributable net profit of 83.724 million yuan, down 26.25%.
Source:
- finance.sina.cn
Sep 29, 2026, 07:49 UTC
Jindawei and its subsidiaries Inner Mongolia Jindawei Pharmaceutical and Jindawei Biotechnology (Jiangsu) received a Chinese invention patent for a chondroitin fermentation production control method from the National Intellectual Property Administration.
Source:
- finance.sina.cn
Aug 25, 2026, 11:13 UTC
Kingvit Co., Ltd. announced its first-half 2026 results: revenue of 1.773 billion yuan, up 2.58% year-on-year, and net profit attributable to shareholders of 170 million yuan, down 31.23% year-on-year.
Source:
- finance.sina.cn
Aug 3, 2026, 08:51 UTC
Kingdawei announced that as of July 31, 2026, it had repurchased 11,362,987 shares for a total of 162 million yuan, under a buyback plan launched on May 6, 2026, with a scale of 200 million to 400 million yuan.
Source:
- finance.sina.cn
- finance.sina.cn
Jul 20, 2026, 07:46 UTC
Jindawei and its subsidiary received a patent certificate for a method of separating and purifying pyrroloquinoline quinone disodium salt, granted by the China National Intellectual Property Administration.
Source:
- finance.sina.cn

002626.SZ

Kingdomway disclosed first-three-quarter 2026 revenue of 2.636 billion yuan, up 1.22% year over year, and attributable net profit of 254 million yuan, down 29.67%.

Kingdomway disclosed third-quarter 2026 revenue of 863 million yuan, down 1.46% year over year, and attributable net profit of 83.724 million yuan, down 26.25%.

Jindawei and its subsidiaries Inner Mongolia Jindawei Pharmaceutical and Jindawei Biotechnology (Jiangsu) received a Chinese invention patent for a chondroitin fermentation production control method from the National Intellectual Property Administration.

Kingvit Co., Ltd. announced its first-half 2026 results: revenue of 1.773 billion yuan, up 2.58% year-on-year, and net profit attributable to shareholders of 170 million yuan, down 31.23% year-on-year.

Kingdawei announced that as of July 31, 2026, it had repurchased 11,362,987 shares for a total of 162 million yuan, under a buyback plan launched on May 6, 2026, with a scale of 200 million to 400 million yuan.

Jindawei and its subsidiary received a patent certificate for a method of separating and purifying pyrroloquinoline quinone disodium salt, granted by the China National Intellectual Property Administration.